New Triple-Threat attack on deadly bile duct cancer shows early promise
NCT ID NCT05668884
Summary
This study is testing a combination of three drugs—two chemotherapy drugs (GEMOX), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors, control the disease, extend survival, and potentially make surgery an option for some patients. Researchers will closely monitor how well the treatment works and its side effects in about 93 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.